[PLXS] Plexus Corp Thesis 2026: Healthcare Aerospace EMS Drives High Mix Complex Product Realization Capital Return

Key Takeaways

• PLXS FY2025 revenue ~$4.10-4.60B (+5-15% YoY) with adj. EPS ~$6.50-7.50 reflecting continued ~$1.85-2.10B aggregate Healthcare/Life Sciences + ~$1.50-1.75B aggregate Industrial + ~$0.65-0.80B aggregate Aerospace/Defense market sector revenue mix under continued President + CEO Todd Kelsey since 2016 (~9-year tenure as Plexus CEO; selected post-2016 succession from Dean Foate retirement after ~14-year tenure 2002-2016; selected primary architect of post-2016 strategic focus toward Healthcare/Life Sciences + Aerospace/Defense + Industrial high-complexity low-to-mid-volume high-mix EMS positioning + selected various aggregate post-2016-2025 manufacturing footprint optimization).
• Healthcare/Life Sciences + Aerospace/Defense EMS Pipeline (~$2.50-2.90B Revenue): ~$2.50-2.90B aggregate Healthcare/Life Sciences + Aerospace/Defense market sector revenue (58-63% revenue mix); selected primary Healthcare/Life Sciences ($1.85-2.10B; selected primary medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics + selected various aggregate FDA-regulated ISO 13485 manufacturing + cleanroom + selected various aggregate $1.5-2.5B aggregate Healthcare/Life Sciences funnel) + selected various aggregate Aerospace/Defense ($0.65-0.80B; selected primary commercial aerospace + defense electronics + radar + avionics + space + selected various aggregate AS9100 + ITAR + selected various aggregate ~$1.0-2.0B aggregate Aerospace/Defense funnel); selected various aggregate ~$3.0-4.5B aggregate trailing 12-month total new program wins funnel.
• Industrial EMS + Engineering Solutions Pipeline (~$1.50-1.75B Revenue): ~$1.50-1.75B aggregate Industrial market sector revenue (~37-42% revenue mix); selected primary Industrial (selected primary semiconductor capital equipment + test & measurement + factory automation + energy + selected various aggregate broadband + networking + selected various aggregate ~$2.0-3.0B aggregate Industrial funnel) + selected various aggregate Engineering Solutions (selected primary product design + development + sustaining engineering + value-add manufacturing engineering + selected various aggregate ~10-15% aggregate Engineering Solutions attach rate on new program wins + selected various aggregate ~higher gross margin engineering content) + selected various aggregate Aftermarket Services (selected primary repair + refurbishment + reverse logistics + selected various aggregate); selected various aggregate post-2024 semiconductor capital equipment + factory automation cyclical recovery + Industrial demand normalization.
• Capital position + balance sheet: ~$0.00 aggregate annual dividend (no regular dividend; selected primary buyback-focused capital return); ~$100-300M aggregate FY2025 buybacks; aggregate capital return ~$100-300M FY2025 (~100% via buybacks); aggregate cash + investments ~$0.3-0.5B; ~$0.3-0.5B aggregate gross debt + ~$0.0-0.2B aggregate net debt; net leverage ~~0-0.8x Net Debt/EBITDA; non-investment-grade BB+/Ba1 credit rating; ~26-28M aggregate diluted shares.
• FY2026 thesis catalysts: Healthcare/Life Sciences + Aerospace/Defense EMS pipeline (~$2.50-2.90B + ~$1.5-2.5B Healthcare/Life Sciences funnel + $1.0-2.0B Aerospace/Defense funnel + FDA + AS9100 + ITAR regulated manufacturing moat) + Industrial EMS + Engineering Solutions pipeline ($1.50-1.75B + ~$2.0-3.0B Industrial funnel + Engineering Solutions ~10-15% attach rate + post-2024 semiconductor capital equipment + factory automation cyclical recovery) + ~$100-300M aggregate FY2025 buybacks + Todd Kelsey high-complexity EMS focus execution.

Company Background

Plexus Corp. (NASDAQ: PLXS) is a US electronics manufacturing services (EMS) + engineering solutions provider, founded 1979 in Neenah Wisconsin (~46-year heritage; selected primary post-1979 founding focus on complex low-to-mid-volume high-mix electronics product realization + selected post-1986 NASDAQ IPO). Selected post-1986 NASDAQ listing; selected post-1986-2025 selected various aggregate global manufacturing + engineering footprint expansion (selected various aggregate US + Mexico + Malaysia + China + Romania + Thailand + selected various aggregate ~25+ aggregate global sites); selected post-2016 Todd Kelsey CEO succession from Dean Foate retirement; selected post-2016-2025 selected various aggregate Healthcare/Life Sciences + Aerospace/Defense + Industrial high-complexity EMS focus + selected various aggregate manufacturing footprint optimization; HQ Neenah Wisconsin; ~20,000-22,000 employees globally.

PLXS operates 1 reportable segment with 3 market sectors: Healthcare/Life Sciences (~45-48% revenue mix; ~$1.85-2.10B) + Industrial (~37-42% revenue mix; ~$1.50-1.75B) + Aerospace/Defense (~14-18% revenue mix; ~$0.65-0.80B). Healthcare/Life Sciences: medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics + FDA-regulated ISO 13485 manufacturing. Industrial: semiconductor capital equipment + test & measurement + factory automation + energy + broadband + networking. Aerospace/Defense: commercial aerospace + defense electronics + radar + avionics + space + AS9100 + ITAR. Geographic mix (manufacturing): Americas ~35-40% + Asia Pacific ~45-50% + EMEA ~10-15%. Engineering Solutions: ~10-15% attach rate on new program wins.

Capital position: ~$0.00 aggregate annual dividend (no regular dividend; buyback-focused capital return); ~$100-300M aggregate FY2025 buybacks; aggregate capital return ~$100-300M FY2025; aggregate cash + investments ~$0.3-0.5B; net leverage ~~0-0.8x Net Debt/EBITDA; non-investment-grade BB+/Ba1 credit rating; ~26-28M aggregate diluted shares.

Healthcare/Life Sciences + Aerospace/Defense EMS Pipeline (~$2.50-2.90B Revenue)

The Healthcare/Life Sciences + Aerospace/Defense EMS pipeline is PLXS's foundation thesis: ~$2.50-2.90B aggregate Healthcare/Life Sciences + Aerospace/Defense market sector revenue (58-63% revenue mix); selected primary Healthcare/Life Sciences ($1.85-2.10B; selected primary medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics + selected various aggregate FDA-regulated ISO 13485 manufacturing + cleanroom + selected various aggregate $1.5-2.5B aggregate Healthcare/Life Sciences funnel) + selected various aggregate Aerospace/Defense ($0.65-0.80B; selected primary commercial aerospace + defense electronics + radar + avionics + space + selected various aggregate AS9100 + ITAR + selected various aggregate ~$1.0-2.0B aggregate Aerospace/Defense funnel); selected various aggregate ~$3.0-4.5B aggregate trailing 12-month total new program wins funnel.

FY2025 Healthcare/Life Sciences + Aerospace/Defense EMS dynamics ($2.50-2.90B aggregate revenue): selected continued post-2024 ~+5-12% aggregate Healthcare/Life Sciences + Aerospace/Defense market sector revenue growth (selected primary Healthcare/Life Sciences medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics demand + selected various aggregate ~$1.5-2.5B aggregate Healthcare/Life Sciences funnel + selected various aggregate Aerospace/Defense commercial aerospace + defense electronics + radar + avionics + space demand + selected various aggregate ~$1.0-2.0B aggregate Aerospace/Defense funnel) + ~$2.50-2.90B aggregate Healthcare/Life Sciences + Aerospace/Defense market sector revenue + selected various aggregate ~$3.0-4.5B aggregate trailing 12-month total new program wins funnel + selected various aggregate FDA + AS9100 + ITAR regulated manufacturing moat. Selected post-2024 ~$4.00-4.60 incremental annual EPS contribution as Healthcare/Life Sciences + Aerospace/Defense EMS pipeline drives incremental high-complexity margin.

FY2026 catalyst: continued Healthcare/Life Sciences + Aerospace/Defense EMS pipeline + ~$4.00-4.60 incremental annual EPS contribution under continued Todd Kelsey leadership (~9-year tenure). Selected aggregate ~$2.65-3.05B aggregate FY2026 Healthcare/Life Sciences + Aerospace/Defense market sector revenue + selected various ~+5-10% aggregate growth + selected various aggregate ~$1.6-2.7B aggregate Healthcare/Life Sciences funnel + selected various aggregate ~$1.1-2.2B aggregate Aerospace/Defense funnel + selected various aggregate ~$3.2-4.8B aggregate trailing 12-month total new program wins funnel + selected various aggregate FDA + AS9100 + ITAR regulated manufacturing moat + selected various aggregate medical device + diagnostic + commercial aerospace + defense electronics demand. Risks: Jabil (JBL, ~$15-18B Mcap; #2 global EMS + Healthcare + Aerospace) + Flex (FLEX, ~$15-18B; #1 global EMS) + Celestica (CLS, ~$10-13B; EMS + Connectivity & Cloud Solutions) + Sanmina (SANM, ~$4-6B; EMS + Healthcare + Aerospace) + Benchmark Electronics (BHE, ~$1-2B; EMS + Healthcare + Aerospace) + Kimball Electronics (KE, ~$0.5-1B; EMS + Healthcare + Automotive) + Integer Holdings (ITGR, ~$4-6B; medical device contract manufacturing) + Cretex Medical (private; medical device contract manufacturing) + selected various aggregate global EMS + medical device + aerospace contract manufacturing competitive considerations + Healthcare/Life Sciences + Aerospace/Defense end-market cycle considerations + medical device + diagnostic + commercial aerospace + defense electronics demand cycle considerations + selected various aggregate FDA + AS9100 + ITAR regulatory considerations + selected various aggregate customer concentration considerations.

Industrial EMS + Engineering Solutions Pipeline (~$1.50-1.75B Revenue)

The Industrial EMS + Engineering Solutions pipeline is PLXS's primary cyclical recovery thesis: ~$1.50-1.75B aggregate Industrial market sector revenue (~37-42% revenue mix); selected primary Industrial (selected primary semiconductor capital equipment + test & measurement + factory automation + energy + selected various aggregate broadband + networking + selected various aggregate ~$2.0-3.0B aggregate Industrial funnel) + selected various aggregate Engineering Solutions (selected primary product design + development + sustaining engineering + value-add manufacturing engineering + selected various aggregate ~10-15% aggregate Engineering Solutions attach rate on new program wins + selected various aggregate ~higher gross margin engineering content) + selected various aggregate Aftermarket Services (selected primary repair + refurbishment + reverse logistics + selected various aggregate); selected various aggregate post-2024 semiconductor capital equipment + factory automation cyclical recovery + Industrial demand normalization.

FY2025 Industrial EMS + Engineering Solutions dynamics: selected primary ~$1.50-1.75B aggregate Industrial market sector revenue + selected various aggregate semiconductor capital equipment + test & measurement + factory automation + energy + broadband + networking + selected various aggregate ~$2.0-3.0B aggregate Industrial funnel + selected various aggregate Engineering Solutions ~10-15% aggregate attach rate on new program wins + selected various aggregate ~higher gross margin engineering content + selected various aggregate post-2024 semiconductor capital equipment + factory automation cyclical recovery (selected primary post-2023-2024 semiconductor capital equipment + factory automation customer inventory destocking + selected various aggregate FY2025 cyclical recovery) + selected various aggregate Industrial demand normalization. Selected post-2024 ~$2.50-2.90 incremental annual EPS contribution as Industrial EMS + Engineering Solutions pipeline drives incremental cyclical recovery margin.

FY2026 catalyst: continued Industrial EMS + Engineering Solutions pipeline + ~$2.50-2.90 incremental EPS contribution. Selected aggregate ~$1.60-1.90B aggregate FY2026 Industrial market sector revenue + selected various aggregate ~+5-12% aggregate growth + selected various aggregate ~$2.2-3.3B aggregate Industrial funnel + selected various aggregate semiconductor capital equipment + factory automation cyclical recovery continuation + selected various aggregate Engineering Solutions ~10-15% aggregate attach rate expansion + selected various aggregate higher gross margin engineering content growth + selected various aggregate Aftermarket Services expansion + selected various aggregate Industrial demand normalization. Risks: Jabil + Flex + Celestica + Sanmina + Benchmark Electronics + Kimball Electronics + Fabrinet (FN, ~$8-10B Mcap; optical + EMS) + IEC Electronics (private) + SMTC (private) + selected various aggregate global EMS + Industrial contract manufacturing competitive considerations + semiconductor capital equipment cycle considerations (selected primary ASML + Applied Materials + Lam Research + KLA capex cycle) + factory automation cycle considerations + test & measurement cycle considerations + Industrial end-market cycle considerations + selected various aggregate customer concentration considerations + selected various aggregate manufacturing footprint optimization considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0.00 aggregate annual dividend (no regular dividend; selected primary buyback-focused capital return) + ~$100-300M aggregate FY2025 buybacks + aggregate capital return ~$100-300M FY2025 (~100% via buybacks) + aggregate cash + investments ~$0.3-0.5B + ~$0.3-0.5B aggregate gross debt + ~$0.0-0.2B aggregate net debt + net leverage ~~0-0.8x Net Debt/EBITDA + non-investment-grade BB+/Ba1 credit rating + ~26-28M aggregate diluted shares + weighted average debt maturity ~3-5 years.

FY2026 catalyst: continued ~$100-350M aggregate annual capital return + selected continued buyback-focused capital return policy + selected various aggregate ~$100-300M aggregate annual buybacks + selected continued ~~0-0.8x net leverage + selected various aggregate potential ~FY2026-FY2027 dividend initiation considerations (post-cyclical recovery free cash flow generation) + selected continued non-investment-grade BB+/Ba1 credit rating. Selected ~~0-0.8x net leverage discipline + selected high-complexity EMS free cash flow generation + selected various aggregate manufacturing footprint optimization support continued buyback-focused capital return + Healthcare/Life Sciences + Aerospace/Defense + Industrial high-complexity EMS capacity + selected various aggregate working capital management.

Key Core Metrics

• FY2025 revenue ~$4.10-4.60B (+5-15% YoY) vs $3.96B FY2024; adj. EPS ~$6.50-7.50
• 1 reportable segment with 3 market sectors: Healthcare/Life Sciences ~45-48% ($1.85-2.10B) + Industrial ~37-42% ($1.50-1.75B) + Aerospace/Defense ~14-18% ($0.65-0.80B)
• Geographic mix (manufacturing): Americas ~35-40% + Asia Pacific ~45-50% + EMEA ~10-15%
• Healthcare/Life Sciences: medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics + FDA-regulated ISO 13485 manufacturing + cleanroom
• Industrial: semiconductor capital equipment + test & measurement + factory automation + energy + broadband + networking
• Aerospace/Defense: commercial aerospace + defense electronics + radar + avionics + space + AS9100 + ITAR
• Healthcare/Life Sciences funnel: ~$1.5-2.5B aggregate
• Aerospace/Defense funnel: ~$1.0-2.0B aggregate
• Industrial funnel: ~$2.0-3.0B aggregate
• Trailing 12-month total new program wins funnel: ~$3.0-4.5B aggregate
• Engineering Solutions attach rate on new program wins: ~10-15% aggregate
• Global manufacturing + engineering footprint: ~25+ aggregate global sites (US + Mexico + Malaysia + China + Romania + Thailand)
• post-2024 semiconductor capital equipment + factory automation cyclical recovery + Industrial demand normalization
• Aggregate adj. EBITDA: ~$0.30-0.40B FY2025
• Net leverage ~~0-0.8x Net Debt/EBITDA
• ~26-28M aggregate diluted shares; ~$100-300M total capital return FY2025
• No regular dividend (buyback-focused capital return)
• ~$100-300M aggregate FY2025 buybacks
• Non-investment-grade BB+/Ba1 credit rating
• ~20,000-22,000 employees globally
• Todd Kelsey CEO since 2016 (~9-year tenure)
• HQ Neenah Wisconsin

Market Evaluation

PLXS FY2026 market evaluation: at ~$130-200 share price + ~26-28M aggregate diluted shares = ~$3.5-5.5B market cap; no regular dividend + ~$100-300M aggregate annual buyback capacity. Selected primary PLXS peers: Jabil (JBL, ~$15-18B Mcap; #2 global EMS + Healthcare + Aerospace) + Flex (FLEX, ~$15-18B; #1 global EMS) + Celestica (CLS, ~$10-13B; EMS + Connectivity & Cloud Solutions) + Sanmina (SANM, ~$4-6B; EMS + Healthcare + Aerospace) + Benchmark Electronics (BHE, ~$1-2B; EMS + Healthcare + Aerospace) + Kimball Electronics (KE, ~$0.5-1B; EMS + Healthcare + Automotive) + Fabrinet (FN, ~$8-10B; optical + EMS) + Integer Holdings (ITGR, ~$4-6B; medical device contract manufacturing) + TE Connectivity (TEL, ~$45-55B; connectors + sensors) + Amphenol (APH, ~$80-100B; connectors + sensors) + selected various aggregate global EMS + medical device + aerospace contract manufacturing companies. Selected PLXS ~18-28x P/E (high-complexity low-to-mid-volume high-mix EMS with Healthcare/Life Sciences + Aerospace/Defense + Industrial FDA + AS9100 + ITAR regulated manufacturing moat + Engineering Solutions attach rate + post-2024 semiconductor capital equipment + factory automation cyclical recovery) + selected ~10-14x EV/EBITDA + no regular dividend + selected aggregate ~$4.40-4.95B aggregate FY2026 revenue + selected aggregate ~$7.25-8.50 aggregate FY2026 EPS + selected aggregate ~$100-350M aggregate FY2026 capital return + selected aggregate Healthcare/Life Sciences + Aerospace/Defense EMS + Industrial EMS + Engineering Solutions pipeline. FY2026 base case: ~$4.40-4.95B aggregate revenue + ~$7.25-8.50 adj. EPS + ~$100-350M aggregate capital return. Bull case: Healthcare/Life Sciences + Aerospace/Defense EMS pipeline acceleration (medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics demand + commercial aerospace + defense electronics + radar + avionics + space demand + ~$1.6-2.7B Healthcare/Life Sciences funnel + ~$1.1-2.2B Aerospace/Defense funnel) + Industrial EMS + Engineering Solutions pipeline acceleration (semiconductor capital equipment + factory automation cyclical recovery continuation + Engineering Solutions attach rate expansion + ~$2.2-3.3B Industrial funnel) drives ~$4.70-5.25B aggregate revenue + ~$8.50-10.00 EPS. Bear case: Jabil + Flex + Celestica + Sanmina + Benchmark + Kimball + Fabrinet + Integer + Cretex Medical competitive intensification + Healthcare/Life Sciences + Aerospace/Defense end-market cycle considerations + semiconductor capital equipment cycle considerations (ASML + Applied Materials + Lam Research + KLA capex cycle) + factory automation cycle considerations + Industrial end-market cycle considerations + customer concentration considerations + manufacturing footprint optimization considerations + post-2016 Todd Kelsey CEO succession planning considerations (~9-year tenure) drives ~$4.00-4.30B revenue + ~$5.75-6.75 EPS. The thesis depends on Healthcare/Life Sciences + Aerospace/Defense EMS + Industrial EMS + Engineering Solutions + FDA + AS9100 + ITAR regulated manufacturing moat + post-2024 semiconductor capital equipment + factory automation cyclical recovery + Todd Kelsey high-complexity EMS focus execution.